{
    "organizations": [],
    "uuid": "d84b3e33375f04582181223eddd22ecea22a2d7b",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/02/07/globe-newswire-intercept-to-report-2017-full-year-financial-results-on-february-14-and-present-at-upcoming-conferences.html",
    "ord_in_thread": 0,
    "title": "Intercept to Report 2017 Full Year Financial Results on February 14 and Present at Upcoming Conferences",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "NEW YORK, Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it will report its fourth quarter and full year 2017 financial results prior to the NASDAQ market open on Wednesday, February 14, 2018. Intercept management will conduct a conference call and audio webcast on Wednesday, February 14, 2018 at 8:30 a.m. Eastern Time to discuss these results.\nIntercept management will also be presenting at the following investor conferences:\nLEERINK Partners 7th Annual Global Healthcare Conference on February 15, 2018 at 2:00 p.m. Eastern Time 2018 RBC Capital Markets Global Healthcare Conference on February 21, 2018 at 10:00 a.m. Eastern Time 38 th Annual Cowen Health Care Conference on March 12, 2018 at 2:10 p.m. Eastern Time\nWebcast information for these events will be available on the Investors page of Intercept's website at http://ir.interceptpharma.com . Archived webcasts will be available on Intercept's website for approximately two weeks.\nAbout Intercept\nIntercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in New York, Intercept now has operations in the United States, Europe and Canada.\nCONTACT: For more information about\nIntercept Pharmaceuticals, please contact:\nIntercept Pharmaceuticals:\nMark Vignola\n+1-646-747-1000\ninvestors@interceptpharma.com\nMedia inquiries: media@interceptpharma.com\nInvestor inquiries: investors@interceptpharma.com\nSource:Intercept Pharmaceuticals, Inc.",
    "published": "2018-02-08T00:05:00.000+02:00",
    "crawled": "2018-02-08T02:16:36.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "new",
        "york",
        "intercept",
        "pharmaceutical",
        "nasdaq",
        "icpt",
        "biopharmaceutical",
        "company",
        "focused",
        "development",
        "commercialization",
        "novel",
        "therapeutic",
        "treat",
        "progressive",
        "liver",
        "disease",
        "today",
        "announced",
        "report",
        "fourth",
        "quarter",
        "full",
        "year",
        "financial",
        "result",
        "prior",
        "nasdaq",
        "market",
        "open",
        "wednesday",
        "february",
        "intercept",
        "management",
        "conduct",
        "conference",
        "call",
        "audio",
        "webcast",
        "wednesday",
        "february",
        "eastern",
        "time",
        "discus",
        "result",
        "intercept",
        "management",
        "also",
        "presenting",
        "following",
        "investor",
        "conference",
        "leerink",
        "partner",
        "7th",
        "annual",
        "global",
        "healthcare",
        "conference",
        "february",
        "eastern",
        "time",
        "rbc",
        "capital",
        "market",
        "global",
        "healthcare",
        "conference",
        "february",
        "eastern",
        "time",
        "th",
        "annual",
        "cowen",
        "health",
        "care",
        "conference",
        "march",
        "eastern",
        "time",
        "webcast",
        "information",
        "event",
        "available",
        "investor",
        "page",
        "intercept",
        "website",
        "http",
        "archived",
        "webcasts",
        "available",
        "intercept",
        "website",
        "approximately",
        "two",
        "week",
        "intercept",
        "intercept",
        "biopharmaceutical",
        "company",
        "focused",
        "development",
        "commercialization",
        "novel",
        "therapeutic",
        "treat",
        "progressive",
        "liver",
        "disease",
        "including",
        "primary",
        "biliary",
        "cholangitis",
        "pbc",
        "nonalcoholic",
        "steatohepatitis",
        "nash",
        "primary",
        "sclerosing",
        "cholangitis",
        "psc",
        "biliary",
        "atresia",
        "founded",
        "new",
        "york",
        "intercept",
        "operation",
        "united",
        "state",
        "europe",
        "canada",
        "contact",
        "information",
        "intercept",
        "pharmaceutical",
        "please",
        "contact",
        "intercept",
        "pharmaceutical",
        "mark",
        "vignola",
        "investor",
        "medium",
        "inquiry",
        "medium",
        "investor",
        "inquiry",
        "investor",
        "source",
        "intercept",
        "pharmaceutical",
        "inc"
    ]
}